Medical devices, prescription drugs boost JnJ earning in Q4
Washington: Growing prescription drug and medical device sales nudged Johnson & Johnson past fourth-quarter earnings expectations, and the health care giant's COVID-19 vaccine gained momentum as well.
J&J's one-shot vaccine rang up USD 1.62 billion in sales in the last quarter of 2021, or more than double what it had recorded before the quarter, as drugstores and clinics started doling out booster shots. The vaccine wound up bringing in USD 2.38 billion last year, or slightly less than what company leaders have said they expected.
J&J said Tuesday that it forecasts vaccine sales of USD 3 billion to USD 3.5 billion this year too, as countries continue to fight variants of the coronavirus. Much of J&J's vaccine sales came from outside the United States, where regulators said last month that most Americans should receive vaccines from Pfizer or Moderna instead of J&J's version due to the rare blood clotting problem tied to the shot. J&J has said it doesn't intend to profit from the vaccine.
Aside from growing vaccine sales, Johnson & Johnson also saw sales of its blood cancer treatment Darzalex jump 31 per cent to about USD 1.65 billion. Total sales from the company's largest business, pharmaceuticals, jumped more than 16 per cent to USD 14.29 billion in the quarter. Medical device sales also grew 4 per cent to about USD 6.9 billion, even though the segment was still hurt by the ongoing pandemic, which has forced patients and hospitals to postpone surgeries and other care.
Johnson & Johnson said in November it will focus on those two segments by splitting off its consumer health business, which sells Band Aids and beauty products, into a separate, publicly traded company. J&J has said it expects that separation to take place over the next couple years.
That segment brought in USD 3.66 billion in sales during the quarter.
Overall, the world's biggest maker of health care products earned USD 4.74 billion in the fourth quarter, while sales grew 10 per cent to USD 24.8 billion.
Research and development expenses also jumped 17 per cent to USD 4.7 billion in the quarter.
Adjusted earnings totaled USD 2.13 per share, or a penny better than expected. Wall Street had expected revenue of USD 25.28 billion, according to FactSet.
J& J also debuted a strong 2022 forecast of per-share earnings between USD 10.40 and USD 10.60. That's better than the USD 10.35 Wall Street had been projecting. Shares of J&J, which is a component of the Dow Jones Industrial Average, were flat before the opening bell Tuesday amid a broad retreat by U.S. markets.
Read also: JnJ COVID booster 85 percent effective against Omicron hospitalisation: SAMRC
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.